These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 33400690)
1. Direct conversion of osteosarcoma to adipocytes by targeting TNIK. Hirozane T; Masuda M; Sugano T; Sekita T; Goto N; Aoyama T; Sakagami T; Uno Y; Moriyama H; Sawa M; Asano N; Nakamura M; Matsumoto M; Nakayama R; Kondo T; Kawai A; Kobayashi E; Yamada T JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33400690 [TBL] [Abstract][Full Text] [Related]
2. TNIK inhibition abrogates colorectal cancer stemness. Masuda M; Uno Y; Ohbayashi N; Ohata H; Mimata A; Kukimoto-Niino M; Moriyama H; Kashimoto S; Inoue T; Goto N; Okamoto K; Shirouzu M; Sawa M; Yamada T Nat Commun; 2016 Aug; 7():12586. PubMed ID: 27562646 [TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Lee Y; Jung JI; Park KY; Kim SA; Kim J Oncotarget; 2017 Jun; 8(25):41091-41101. PubMed ID: 28467797 [TBL] [Abstract][Full Text] [Related]
4. Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT). Sun Y; Gao X; Wu P; Wink M; Li J; Dian L; Liang Z Phytomedicine; 2019 Oct; 63():153015. PubMed ID: 31302315 [TBL] [Abstract][Full Text] [Related]
5. PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity. Basu-Roy U; Han E; Rattanakorn K; Gadi A; Verma N; Maurizi G; Gunaratne PH; Coarfa C; Kennedy OD; Garabedian MJ; Basilico C; Mansukhani A Oncotarget; 2016 Sep; 7(38):60954-60970. PubMed ID: 27528232 [TBL] [Abstract][Full Text] [Related]
6. Discovery of 3,4-Dihydrobenzo[ Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886 [TBL] [Abstract][Full Text] [Related]
7. Emergence of TNIK inhibitors in cancer therapeutics. Yamada T; Masuda M Cancer Sci; 2017 May; 108(5):818-823. PubMed ID: 28208209 [TBL] [Abstract][Full Text] [Related]
8. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity. Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785 [TBL] [Abstract][Full Text] [Related]
9. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma. Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327 [TBL] [Abstract][Full Text] [Related]
10. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Shitashige M; Satow R; Jigami T; Aoki K; Honda K; Shibata T; Ono M; Hirohashi S; Yamada T Cancer Res; 2010 Jun; 70(12):5024-33. PubMed ID: 20530691 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730 [TBL] [Abstract][Full Text] [Related]
12. Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma. Wang H; Tao Y; Han J; Shen J; Mu H; Wang Z; Wang J; Jin X; Zhang Q; Yang Y; Lin J; Sun M; Ma X; Ren L; LeBlanc AK; Xu J; Hua Y; Sun W Cell Oncol (Dordr); 2024 Oct; 47(5):1845-1861. PubMed ID: 39115605 [TBL] [Abstract][Full Text] [Related]
13. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Chon HJ; Lee Y; Bae KJ; Byun BJ; Kim SA; Kim J Amino Acids; 2016 Jul; 48(7):1591-9. PubMed ID: 26995282 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer. Masuda M; Sawa M; Yamada T Pharmacol Ther; 2015 Dec; 156():1-9. PubMed ID: 26542362 [TBL] [Abstract][Full Text] [Related]
15. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158 [TBL] [Abstract][Full Text] [Related]
16. Targeting the Wnt signaling pathway in colorectal cancer. Sawa M; Masuda M; Yamada T Expert Opin Ther Targets; 2016; 20(4):419-29. PubMed ID: 26439805 [TBL] [Abstract][Full Text] [Related]
17. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma. Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma. Yan J; Wang Q; Zou K; Wang L; Schwartz EB; Fuchs JR; Zheng Z; Wu J Mol Med Rep; 2015 Jul; 12(1):498-502. PubMed ID: 25760445 [TBL] [Abstract][Full Text] [Related]
19. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells. Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]